Epigenic Therapeutics Invited to 2025 Chardan's 9th Annual Genetic Medicines Conference in New York

Shanghai, China, October 09, 2025, Epigenic Therapeutics, a clinical-stage biotech company focused on developing innovative epigenetic modulation therapies, today announced that it has been invited to join the “Chardan's 9th Annual Genetic Medicines Conference” held on October 20-21, 2025 in New York City. Dr. Bob Zhang, Co-founder & CEO of Epigenic, will share insights on the company’s innovative technology platform, pipeline progress and development strategy, while also discussing the application prospects of epigenetic modulation technology.